Business
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, forecasts new medical breakthroughs in the fight against pancreatic cancer over the next decade. Rece
About this update from Propanc Biopharma, Inc.
[{"type":"image","alt":"Propanc Biopharma, Inc.","displaySize":"","headline":null,"caption":"Propanc Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3CVW7M..8.qp0Zog.Hg.9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b","width":300,"height":68},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3CVW7M..8.qp0Zog.Hg.9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b","width":300,"height":68}},"lazy":false},{"type":"text","content":"Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26","length":80,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, forecasts new medical breakthroughs in the fight against pancreatic cancer over the next decade. Recent developments in treatment reflect a level of progress that has been difficult to achieve in this field. Clinical stage companies like Revolution Medicines Inc. and Erasca Inc. have demonstrated significant advancements in this field.","length":656,"tagName":"p"},{"type":"text","content":"New clinical data from a late-stage trial targeting KRAS mutations, which are present in many pancreatic cancer cases, showed a meaningful improvement in overall survival. Patients receiving the targeted therapy lived approximately 13 months compared to about 7 months with standard treatment. For a disease where outcomes have remained largely unchanged for decades, this represents an important step forward.","length":410,"tagName":"p"},{"type":"text","content":"At the same time, additional data from combination therapy approaches are reinforcing a broader trend. In one study, a treatment designed to improve tumor penetration and support immune response increased one year survival rates to roughly 42%, compared to 22% with chemotherapy alone. These types of results are ...